Eftychia Demerouti
Overview
Explore the profile of Eftychia Demerouti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
82
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Demerouti E, Frantzeskaki F, Adamidi T, Anthi A, Filiou E, Karyofyllis P, et al.
Hellenic J Cardiol
. 2025 Feb;
PMID: 39983868
Pulmonary arterial hypertension (PAH) is a life-threatening condition characterized by excessive proliferation of pulmonary artery vessels. Despite significant advancements in treatment strategies over recent years, mortality rates remain high. The...
2.
Patsiou V, Arvanitaki A, Farmakis I, Anthi A, Demerouti E, Apostolopoulou S, et al.
Int J Cardiol
. 2024 Dec;
421():132894.
PMID: 39662747
Background: Pulmonary arterial hypertension (PAH) is a severe complication among adult patients with congenital heart disease (ACHD). This study presents real-world data on risk stratification, pharmacotherapy and survival rates in...
3.
Karyofyllis P, Demerouti E, Tsetika E, Apostolopoulou S, Tsiapras P, Iakovou I, et al.
Life (Basel)
. 2024 Jul;
14(7).
PMID: 39063629
Haemolytic anaemia represents a risk factor for the development of pulmonary hypertension (PH), currently classified as World Health Organization group 5 PH, and data regarding appropriate therapeutic strategy are limited....
4.
Karyofyllis P, Demerouti E, Habibis P, Apostolopoulou S, Tsetika E, Tsiapras D
Life (Basel)
. 2023 May;
13(5).
PMID: 37240847
Despite the evolution of drug therapy in pulmonary arterial hypertension and the more aggressive treatment approach according to the guidelines, patients continue to have unacceptable mortality rates. Furthermore, specific drug...
5.
Arvanitaki A, Vrana E, Boutsikou M, Anthi A, Apostolopoulou S, Avgeropoulou A, et al.
Pulm Circ
. 2022 Jun;
12(2):e12086.
PMID: 35685948
Whereas younger female patients were diagnosed with idiopathic pulmonary arterial hypertension (IPAH) in 1980s, it is now frequently encountered in elderly patients with cardiovascular comorbidities (CVCs) associated with increased risk...
6.
Karyofyllis P, Demerouti E, Giannakoulas G, Anthi A, Arvanitaki A, Athanassopoulos G, et al.
J Clin Med
. 2022 Apr;
11(8).
PMID: 35456303
Balloon pulmonary angioplasty (BPA) is a novel and promising treatment option for patients with chronic thromboembolic pulmonary hypertension (CTEPH) who are ineligible for pulmonary endarterectomy (PEA) and for those with...
7.
Farmakis I, Karyofyllis P, Frantzeskaki F, Demerouti E, Anthi A, Arvanitaki A, et al.
Hellenic J Cardiol
. 2021 Nov;
64:93-96.
PMID: 34843997
No abstract available.
8.
Demerouti E, Karyofyllis P, Voudris V, Boutsikou M, Anastasiadis G, Anthi A, et al.
J Clin Med
. 2021 Oct;
10(19).
PMID: 34640577
Chronic Thromboembolic Pulmonary Hypertension (CTEPH) is a rare disease with poor prognosis if left untreated, characterized by pulmonary vascular bed obstruction due to unresolving thromboembolic material. The Hellenic pulmonary hypertension...
9.
Grigorian-Shamagian L, Edel K, Esteve-Pastor M, Acena A, Silva C, Delgado-Silva J, et al.
Front Cardiovasc Med
. 2021 Sep;
8:663361.
PMID: 34504874
The main objective of cardiovascular disease (CVD) prevention is to reduce morbidity and mortality. Despite recommendations on evidence-based pharmacological treatment and lifestyle changes, the control of CV risk factors such...
10.
Farmakis I, Demerouti E, Karyofyllis P, Karatasakis G, Stratinaki M, Tsiapras D, et al.
J Clin Med
. 2021 Jul;
10(13).
PMID: 34206876
Pulmonary arterial hypertension (PAH) is characterized by an insult in the pulmonary vasculature, with subsequent right ventricular (RV) adaptation to the increased afterload that ultimately leads to RV failure. The...